Introduction
The severe acute respiratory coronavirus-2 (SARS‐CoV‐2) is responsible for coronavirus disease-19 (COVID‐19) that mostly associates with asymptomatic and mild presentations but may progress in worst cases to severe pneumonia leading to intensive care unit (ICU) admission and acute respiratory distress syndrome (ARDS) requiring respiratory support [
1]. Since the onset of the pandemic, the number of COVID-19 patients has never ceased to rise and has ultimately outstripped hospital/ICU capacity in some areas particularly affected by virus spread. COVID-19 mortality, although currently decreasing, has remained dramatically high especially in patients requiring invasive mechanical ventilation [
1].
An enormous research effort has been consented to describe and understand the mechanisms sustaining altered host immune response to a virus totally unknown of human immune surveillance. Many exploratory non-hypothesis‐driven programs have been deployed in order to decipher immune processes at play in COVID‐19. Through various flow cytometry approaches, transcriptomic strategies, functional testing and multiplex measurement of soluble mediators, most studies compared immune response between groups of COVID-19 patients with increasing severity, i.e., mild/severe/critical [
2‐
5]. These works provided homogenous results describing that, upon hospital arrival, the most severe phenotype associated with inflammatory response (e.g., moderate plasma IL-6 elevation) and altered cellular immunity, i.e., decreased monocyte HLA-DR expression (mHLA-DR) and marked lymphopenia [
6‐
11]. In addition, impaired type I interferons (IFN-I) activity has emerged as a contributor to the disease severity [
12‐
15]. These latter cytokines are crucial components of innate immune response against viruses by ringing a “first alarm” bell. IFN-I have, by themselves, antiviral properties but they also induce the expression of hundreds of IFN-stimulated genes (ISG) inducing cellular antiviral activity, therefore, limiting virus spread [
5].
In contrast, fewer studies focused on longitudinal immune monitoring in hospitalized COVID-19 patients, whereas their hospital stay may last for several weeks [
1]. This is especially true in critically ill COVID-19 patients with ARDS who also present with the highest mortality [
1]. To investigate this particular aspect of COVID-19 immune response, we monitored selected immunological parameters, including IFNα2 measurement and IFN-stimulated genes (ISG) transcriptomic signature, in a group of 64 COVID-19 patients requiring ICU care over a 3-week period after ICU admission.
Methods
Clinical study design, patient population and approval
Between March and May 2020, critically ill patients admitted to three ICUs from academic hospital (Hospices Civils de Lyon, Lyon, France) who presented with pulmonary infection with SARS-CoV-2 confirmed by RT-PCR testing were prospectively included in the study. A flowchart describing the patient datasets used for the different analyses is provided in Additional file
1: Figure S1. Preliminary results from a subgroup of the cohort were published previously [
9]. This project was part of an ongoing prospective observational clinical study (RICO, REA-IMMUNO-COVID). It was approved by ethics committee (Comité de Protection des Personnes Ile de France 1 - N°IRB/IORG #: IORG0009918) under agreement number 2020-A01079-30. This clinical study was registered at ClinicalTrials.gov (NCT04392401). The committee waived the need for written informed consent because the study was observational, with a low risk to patients, and no specific procedure, other than routine blood sampling, was required. Oral information and non-opposition to inclusion in the study were mandatory and were systematically obtained before any blood sample was drawn. This was recorded in patients’ clinical files. If a patient was unable to consent directly, non-opposition was obtained from the patient’s legally authorized representative and reconfirmed from the patient at the earliest opportunity. Inclusion criteria were: patients aged > 18 years, diagnosis of COVID-19 confirmed by RT-PCR testing in one respiratory sample. Inclusion criteria were (1) man or woman aged 18 or over, (2) hospitalization in ICU for SARS-CoV-2 pneumopathy, (3) first hospitalization in ICU, (4) positive diagnosis of SARS-CoV2 infection carried out by PCR or by another approved method in at least one respiratory sample, (5) sampling in the first 24 h after admission to ICU (D0) feasible and (6) patient or next of kin who has been informed of the terms of the study and has not objected to participating. Exclusion criteria were pregnancy, institutionalized patients, inability to obtain informed consent.
Patient characteristics
For each patient, demographics, comorbidities, time from onset of COVID-19 symptoms to ICU admission, initial presentation of the disease in ICU including the ratio of the arterial partial pressure of oxygen to the fractional inspired oxygen (PaO
2/FiO
2 ratio) at admission, antiviral therapy targeting SARS-CoV-2 and organ support were documented. Organ dysfunctions according to sequential organ failure assessment (SOFA) score (range 0–24, with higher scores indicating more severe organ failures) and simplified acute physiology score II (SAPS II; range 0–164, with higher scores indicating greater severity of illness) were documented. Patients were classified in the acute respiratory distress syndrome (ARDS) group if they were invasively ventilated and met the Berlin criteria for ARDS within the first 3 days after ICU admission [
16]. Follow-up included ICU length of stay, in-hospital mortality, day-28 (D28) mortality, day-90 (D90) mortality, as well as occurrence secondary infection based on recommendation from Comité technique des infections nosocomiales et des infections liées aux soins [
17].
Blood samples
Ethylene diamine tetraacetic acid (EDTA-)anticoagulated blood was drawn five times during the first month after ICU admission: within the first 48 h after admission (Day 0: D0), between 72 and 96 h after admission (D3), between D7 and D9 (D7), between D12 and D15 (D12) and between D20 and D25 (D20). Blood was stored at 4–8 °C and processed within 4 h after withdrawal. The numbers of available values for each immune parameter at each time point are presented in Additional file
1: Table S4.
Cytokine measurement
Whole blood was sampled on EDTA tubes and plasma was frozen at − 20 °C within 4 h following blood collection. Cytokine measurement was taken by batches after 1 freeze/thaw cycle using standardized protocols fulfilling clinical and diagnostic laboratories accreditation requirements from the International Organization for Standardization. Plasma concentrations of IL-6, TNF-α, IFN-γ and IL-10 were measured by Simpleplex® technology using ELLA instrument (ProteinSimple®, San Jose, CA), following manufacturer’s instructions. Plasma IFNα2 concentrations were determined by single-molecule Array (SIMOA®) on a HD-1 Analyzer (Quanterix) using a commercial kit for IFN-α2 quantification (Quanterix, Lexington, Mass).
IFN-stimulated genes (ISG) score calculation
Whole blood was collected on PAXgene blood RNA tubes (BD, Grenoble, France) for IFN signature and frozen at − 80 °C until RNA extraction. IFN score was obtained using nCounter® analysis technology (NanoString Technologies, Seattle, WA) by calculating the median of the normalized count of 6 ISGs using standardized protocols fulfilling clinical and diagnostic laboratories accreditation requirements from the International Organization for Standardization. As previously described, six interferon responsive genes were monitored:
SIGLEC1 (sialic acid binding Ig like lectin 1),
IFI27 (interferon alpha inducible protein27),
IFI44L (interferon induced protein 44 like),
IFIT1 (interferon induced protein with tetratricopeptide repeats 1),
ISG15 (interferon-stimulated gene 15) and
RSAD2 (radical S-adenosyl methionine domain-containing 2). Three references genes were also measured:
ACTB (Actin beta),
HPRT1 (hypoxanthine phosphoribosyltransferase 1) and
POLR2A (RNA Polymerase II Subunit A) [
18].
Flow cytometry
T lymphocyte subpopulation immunophenotyping was performed on an automated volumetric flow cytometer from Beckman Coulter (Aquios CL) as previously described [
19]. Monocyte HLA-DR expression and B and NK immunophenotyping were performed using antibodies from Beckman-Coulter and BD Biosciences. The expression of monocyte HLA-DR was determined using the Anti-HLA-DR/Anti-Monocyte Quantibrite assay (BD Biosciences, San Jose, USA). A total number of antibodies bound per cell (AB/C) were quantified using calibration with a standard curve determined with BD Quantibrite phycoerythrin (PE) beads (BD Biosciences) as described elsewhere [
20]. B and NK lymphocyte immunophenotyping was performed using lyophilized antibody panel from Beckman Coulter (Duraclone kit). Data were acquired on a Navios flow cytometer (Beckman Coulter, Hialeah, FL), and flow data were analyzed using Navios software (Beckman Coulter). Enumeration of lymphocyte subpopulations as well as mHLA-DR measurement were performed using standardized protocols fulfilling clinical and diagnostic laboratories accreditation requirements from the International Organization for Standardization.
SARS-CoV-2 detection by semiquantitative PCR
Semiquantitative values of SARS-CoV-2 viral load in upper respiratory samples at ICU admission were retrieved from clinical files for 40 patients. These results were obtained from accredited reference laboratory using RT-PCR technique with validated commercial kits (COBAS® SARS-CoV-2, Roche Diagnostics or reference technique from Pasteur Institute) based on recommendations from the Societé Française de Microbiology after evaluation of analytical performances of the techniques [
21]. Patients were classified into three groups according to SARS-CoV-2 PCR Ct values reflecting respiratory viral load at admission (1) A significant viral excretion (ct value ≤ 33) subsequently divided into two groups: high viral load (Reference Ct value < 27,
n = 12) and medium viral load (Reference Ct value = [27–33],
n = 21); (2) a nonsignificant viral excretion corresponding to a low viral load (Reference Ct value = [33–37],
n = 7).
Statistical analysis
Data are presented as numbers and percentage (qualitative variables) and medians and 25th/75th percentiles (quantitative variables). Chi square or Fisher’s exact test were used for qualitative variables assessment. Quantitative variables were compared with Mann–Whitney U test. For all pairs of immune parameters, Spearman’s rho correlation coefficients were estimated and summarized in a correlation matrix. Kaplan–Meier survival curves were calculated in groups of patients with or without ARDS. The p-value of the log-rank test is given. The level of significance was set at 5%. Data were analyzed using Graphpad Prism version 5.03 (Graphpad Software, La Jolla, USA).
Discussion
Collectively, the present results provide an unbiased description of COVID-19 immuno-inflammatory derangements in critically ill COVID-19 patients focusing on ARDS patients who exhibit the highest mortality. We noted that, upon ICU admission, immune response to SARS-CoV-2 infection presents with similarities with bacterial sepsis [
28,
29]. These include (1) severe lymphopenia affecting all lymphocyte subsets, (2) moderately decreased mHLA-DR and (3) moderately increased plasma cytokine levels showing at the same time both inflammatory (IL-6) and immunosuppressive (IL-10) responses. In addition, we noticed increased plasma IFNα2 levels and ISG score indicating the occurrence of an IFN-I response. This agrees with increased CD169 expression on monocytes (aka siglec-1, one of the six genes of ISG) in COVID-19 patients upon ICU admission [
30]. Thus, the present results do not support a potentially altered IFN-I response in the majority of COVID-19 patients upon ICU admission. However, as IFNα2 concentrations reported elsewhere were higher in less severe/moderate patients (between 1000 and 5000 fg/mL) [
12]; we cannot exclude that the incapacity to mount a full type-I IFN response immediately following SARS-CoV2 infection in some patients may have led to their worsening and ultimately to ICU admission.
These abnormalities (along with decreased plasmacytoid cells [
12,
14,
31]) are reminiscent of the process of age-acquired immunosuppression (also called immunosenescence) observed in elderly people who are, by far, the primary victims of COVID-19. We may hypothesize that evolution of COVID-19 toward increasing severity in this population of old patients is mainly a consequence of this altered immune status [
32‐
35]. For example, previous studies showed the negative correlation between lymphocytes count and pulmonary viral load [
36,
37] while, elsewhere, the magnitude of pulmonary viral load was repeatedly associated with increased mortality [
8,
38‐
43]. In the present work, this is also illustrated by the association between nasopharyngeal viral load and increased mortality, SOFA and IL-6 levels upon admission.
Our results emphasize that ARDS occurrence appears to be an important driver of mortality during COVID-19 progression in ICU patients [
1]. In the present cohort, mortality occurred only in the group of patients with ARDS while all ICU patients without ARDS were released alive from the ICU. This observation makes a strong priority for avoiding progression toward ARDS in COVID-19 patients. After ICU admission, inflammatory response as well as IFN-I activity progressively normalized while immunological cellular parameters remained below references ranges. Thus, as seen in bacterial sepsis, ARDS occurrence in COVID-19 patients may secondarily amplify COVID-19-induced immune alterations either by direct cytotoxic effect and/or by negative anti-inflammatory feedbacks [
28,
29,
32]. This leads to the development of a torpid immunosuppressed status in ARDS patients which may last several weeks [
44].
In such critically ill patients with prolonged ICU stays, this immunosuppressed status presents with deleterious consequences. First, it probably participates in the long duration necessary to eradicate SARS-CoV-2 from the lung in invasively ventilated patients as described elsewhere [
43]. For example, it was shown that the viral shedding in lower respiratory tract lasted almost 30 days in median in critically ill COVID-19 patients [
38,
42]. Second, it most likely contributes to the very high rates of nosocomial infections reported not only in the present study (50%) but also in many others [
26,
27,
45]. In particular, COVID-19 is characterized by astonishing elevated rates of secondary aspergillosis [
46‐
48], a fungal disease usually seen in the most immunosuppressed patients. Such secondary infectious events may explain the persistently elevated TNF-α levels accompanied by increased neutrophil count in COVID-19 patients with ARDS and in non-survivors [
25]. This suggests that in this second step of the disease, i.e., once ARDS occurred, immunostimulation could represent a sound approach to try to promote immune recovery and prevent secondary bacterial and fungal infections.
The most striking result of the present study was to observe similar altered immune response in both surviving and non-surviving ARDS patients over a 3-week follow-up. Thus, the duration of this COVID-19 induced immunosuppressed status remains to be defined. While a recent study observed that the onset of T cell recovery in COVID-19 ICU patients with ARDS started on day 35 [
49], the 3-week ICU follow-up performed in this study may have been too short to distinguish immune trajectories according to outcomes in COVID-19 ARDS patients. Of note, in this latter work [
49], patients with unfavorable outcome presented with increased CD4/CD8 ratio as observed in the present study. We may thus hypothesize that, in ARDS patients, the lack of CD8+T lymphocyte recovery could be a poor prognosis factor [
35,
50].
Being exploratory, our work presents with limitations. First, SARS-CoV2 viral load could not be regularly monitored. Further studies should include strict quantitative evaluation of viral load with standardized tools throughout the monitoring to decipher the duration of viral persistence in the lung and its correlation with immune response and outcomes. Second, functional testing of immune cells was not performed. If available, this should be incorporated in addition with phenotypic markers of immune response [
51‐
53]. This is especially true regarding CD8+T cell functionality in response to SARS-CoV-2 peptides that may help to understand which comes first: CD8 efficiency (and recovery) or virus disappearance. Three, we did not include less severe COVID-19 cohorts in order to explore (with single-molecule array—SIMOA-technology) the magnitude of IFN-I response in patients who correctly eradicated the virus. Last, at the time of first COVID-19 surge in France (corresponding to the patients reported here), optimized care protocols (oxygen, heparin, dexamethasone) were not applied. Therefore, some observations need to be confirmed under the angle of current clinical practice.
Conclusions
In sum, upon patients’ admission to the ICU, pulmonary virus spread is accompanied by an inflammatory response characterized by moderately increased circulating levels of typical inflammatory cytokines (e.g., IL-6 levels usually < 100 pg/mL) [
54‐
57]. At this stage, no obvious observation of altered IFN-I response could be reported. If not appropriately controlled by the immune system [
33], virus replication in lungs and related inflammation may progressively lead to ARDS which appears to be one driver of mortality. Following this acute response leading to pulmonary dysfunction, inflammatory response rapidly declined. As observed in bacterial sepsis [
28,
29], patients subsequently present with a marked delayed immunosuppression. This state of immunosuppression likely prevents efficient virus eradication from the lung, facilitates virus spread outside lungs as illustrated by the deleterious association of persistent viremia and mortality [
58‐
62]. This also probably favors the occurrence of frequent secondary infections with opportunistic pathogens [
26,
27,
47]. All these elements explain the long ICU stay of invasively ventilated COVID-19 patients. In the current 3-week monitoring of ARDS patients, we did not identify any immunological parameter that significantly associated with mortality. Thus, the better understanding of the mechanisms which finally permit survival after several weeks in ICU is a crucial issue for next studies.
Acknowledgements
This work was supported by funds from the Hospices Civils de Lyon, Fondation HCL and Claude Bernard Lyon 1 University/Région Auvergne Rhône-Alpes. The authors would like to thank the clinical teams from all ICUs in HCL who were involved in this project while dedicated to their clinical duties during COVID-19 pandemic as well as patients and their families who agreed to participate to this clinical study. The authors declare no competing financial interest. K Brengel-Pesce is bioMérieux employee. This private company had no role in the study design, result analysis and decision to publish this study.
The names of the individual members of the RICO study group as listed below should be searchable through their individual PubMed records:
Hospices Civils de Lyon, Lyon-Sud University Hospital, Immunology Laboratory: Remi Pescarmona, Lorna Garnier, Christine Lombard, Magali Perret, Marine Villard
Joint Research Unit HCL-bioMérieux: Valérie Cheynet, Filippo Conti
Centre d’Investigation Clinique de Lyon (CIC 1407 Inserm): Marie Groussaud, Marielle Buisson, Laetitia Itah, Inesse Boussaha
Hospices Civils de Lyon, Edouard Herriot Hospital, Immunology Laboratory: Françoise Poitevin-Later, Christophe Malcus, Morgane Gossez
RICO clinical investigators: Florent Wallet, Marie-Charlotte Delignette, Frederic Dailler
Hospices Civils de Lyon, Edouard Herriot Hospital, Medical intensive Care Department: Marie Simon, Auguste Dargent, Pierre-Jean Bertrand, Neven Stevic, Marion Provent
Hospices Civils de Lyon, Edouard Herriot Hospital, Anesthesia and Critical Care Medicine Department: Laurie Bignet, Valérie Cerro
Hospices Civils de Lyon, Croix-Rousse University Hospital, Medical intensive Care Department: Jean-Christophe Richard, Laurent Bitker, Mehdi Mezidi, Loredana Baboi
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.